iQure Pharma

iQure Pharma is a private, clinical-stage biotech founded in 2018 and headquartered in Cambridge, Massachusetts. The company is pioneering a novel neuroprotective strategy by developing small molecules that enhance the function of the EAAT2 glutamate transporter on astrocytes, aiming to treat a broad range of CNS disorders rooted in excitotoxicity. With its lead program, iQ-007, in a Phase 1 trial for epilepsy, the company is validating its platform and expanding into preclinical programs for neurodegeneration and pain. iQure leverages strong academic collaborations and is backed by venture capital investors.

Platform for developing small molecules that enhance the function of the EAAT2 glutamate transporter on astrocytes to restore glutamate homeostasis and combat excitotoxicity in CNS disorders.

Competition includes companies developing NMDA/AMPA receptor antagonists, glutamate release inhibitors, and other neuroprotective strategies. iQure's specific focus on enhancing astrocytic glutamate uptake via EAAT2 is a differentiated approach, but it must prove clinical superiority or better tolerability against existing and emerging standard-of-care treatments.